XML 66 R44.htm IDEA: XBRL DOCUMENT v3.20.4
Stock Based Awards - Additional Information (Detail) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Mar. 20, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Intrinsic value of stock option exercised   $ 600,000 $ 400,000  
Number of shares reserved 3,774,712 3,253,969    
Common stock, voting rights One      
Employee Stock Purchase Plan [Member]        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Percentage of common stock issued and outstanding increase annually 1.00%      
Number of shares reserved       2,500
End date of automatic annual increase of shares reserved for issuance Jan. 01, 2024      
Additional shares issued 50,000      
Common stock, voting rights Immediately after the grant would own stock possessing 5% or more of the total combined voting power or value of our common stock.      
Percentage of stock possessing 5.00%      
Rights to purchase stock that remains outstanding $ 25,000      
Offerings of purchase periods 27 months      
Maximum employee subscription rate 15.00% 15.00%    
Employee Stock Purchase Plan [Member] | Minimum [Member]        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Percentage of purchase price common stock 85.00% 85.00%    
Employee Stock Option [Member]        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Options vesting period 4 years 4 years    
Stock options, weighted-average grant date fair value $ 7.69 $ 4.69    
Tax benefits realized from options and other share-based payment arrangements $ 0 $ 0    
Weighted-average remaining vesting period 2 years 8 months 12 days      
Unrecognized employee stock-based compensation $ 2,900,000      
Incremental compensation costs $ 400,000      
2019 Plan [Member]        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Common stock reserved for future issuance 1,600,703      
Percentage of common stock issued and outstanding increase annually 4.50%      
Equity awards, expiration date Jan. 01, 2029      
Equity incentive plan modification, description The 2019 Plan is a successor to and continuation of all prior plans including the Company’s 2014 Equity Incentive Plan and Aravive Biologics 2017 Equity Incentive Plan and the 2010 Equity Incentive Plan, as amended (Prior Plans).